GREEN HYGIENICS HLDGS INC - GRYN STOCK NEWS

Green Hygienics Holdings Inc. (OTCQB: GRYN) announced corporate updates on November 10, 2022. Due to delays in filing its April 30 and July 31 financial reports, the company has been moved to the Expert Market, limiting visibility and trading options. The Company aims to regain compliance with listing rules through timely filings. Additionally, it is considering refinancing its California property and pursuing a bond offering. Despite challenges, there is a growing demand for organic hemp products, which the Company plans to capitalize on.

Green Hygienics Holdings Inc. (OTCQB: GRYN) has entered the U.S. plant-based food market with an initial purchase order for its hemp protein product from a major exchange-listed company. The global plant protein market is projected to grow from $29.4 billion in 2020 to over $162 billion by 2030. Green Hygienics' proprietary processing methods yield a hemp protein product with 70%-73% protein content, outperforming competitors. This product can be sold through major retailers without strict regulatory limitations, enhancing market opportunities.

Green Hygienics Holdings (OTCQB: GRYN) has provided an update on its business developments and 2021 harvest. The company has focused on non-dilutive financing, pursuing a $100M Green Bond Offering. Major achievements include a comprehensive valuation of $195M, new branding, and operational upgrades. The 2021 hemp harvest is projected to reach 30,000-40,000 pounds, doubling last year's yield. Green Hygienics is also expanding its e-commerce presence with four planned websites to boost cash flow and exploring diverse market opportunities.

Green Hygienics Holdings (OTCQB: GRYN) has provided an update on its 2021 harvest and ongoing business developments. The company is pursuing a $100M Green Bond Offering for acquisitions, having made significant progress, including a valuation of $195M. The 2021 hemp harvest is projected to be between 30,000 and 40,000 pounds, double last year’s output. Plans to launch four e-commerce websites in early 2022 aim to enhance revenue. Additionally, the firm is targeting strategic acquisitions to bolster cash flow, leveraging its ability to cultivate USDA Certified Organic hemp.

Green Hygienics Holdings Inc. (OTCQB: GRYN) announced a green bond offering of US$100 million in Europe. This five-year bond, yielding 7.25%, is set to close around November 30, 2021. The company has engaged Dechert LLP for legal assistance and plans to list the bond on the Luxembourg Stock Exchange. The offering is backed by the publication of the company’s ESG Report and an ongoing business valuation.

Green Hygienics Holdings (OTCQB: GRYN) announced a green bond offering in Europe, totaling US$100 million with a 7.25% yield. This bond will have a five-year term, is not convertible, and does not include warrants. The closing date is projected around November 30, 2021, pending customary conditions. The bond aims to be listed on the Luxembourg Stock Exchange, a leader in green finance. This offering aligns with the release of the company's annual Environmental, Social and Governance Report and a recent business valuation.

Green Hygienics Holdings Inc. (OTCQB: GRYN) has appointed Dr. Francesca Serraino Fiory as the new Chief Scientific Officer. She will head product development and R&D initiatives at the company's biotechnology subsidiary, TruLife Biotech, and manage partnerships with research institutions. Dr. Serraino Fiory has extensive experience in the pharmaceutical industry, having previously worked with Pfizer, Johnson & Johnson, and Perrigo Pharma, where she led regulatory affairs. Her appointment aims to drive sustainable growth and regulatory compliance in product offerings.

Green Hygienics Holdings Inc. (OTCQB: GRYN) has appointed Dr. Francesca Serraino Fiory as the new Chief Scientific Officer. She will lead product development and R&D efforts under the company’s biotech subsidiary, TruLife Biotech, while also forging partnerships with research institutions. Dr. Serraino Fiory has extensive experience in regulatory affairs, having worked at Pfizer and Johnson & Johnson, and has a strong background in both Eastern and Western medicine. The company focuses on cultivating industrial hemp and manufacturing pharmaceutical-grade cannabinoids.